215 related articles for article (PubMed ID: 32283297)
1. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.
Tang Z; Wu C; Wang T; Lao K; Wang Y; Liu L; Muyaba M; Xu P; He C; Luo G; Qian Z; Niu S; Wang L; Wang Y; Xiao H; You Q; Xiang H
Eur J Med Chem; 2016 Aug; 118():328-39. PubMed ID: 27176944
[TBL] [Abstract][Full Text] [Related]
3. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
5. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
[TBL] [Abstract][Full Text] [Related]
6. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
[TBL] [Abstract][Full Text] [Related]
8. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
10. Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
Ning W; Hu Z; Tang C; Yang L; Zhang S; Dong C; Huang J; Zhou HB
J Med Chem; 2018 Sep; 61(18):8155-8173. PubMed ID: 30053783
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.
Ota Y; Itoh Y; Kaise A; Ohta K; Endo Y; Masuda M; Sowa Y; Sakai T; Suzuki T
Angew Chem Int Ed Engl; 2016 Dec; 55(52):16115-16118. PubMed ID: 27882656
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
14. LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP.
Bennesch MA; Segala G; Wider D; Picard D
Nucleic Acids Res; 2016 Oct; 44(18):8655-8670. PubMed ID: 27325688
[TBL] [Abstract][Full Text] [Related]
15. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
[TBL] [Abstract][Full Text] [Related]
16. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
17. E239K mutation abolishes the suppressive effects of lysine-specific demethylase 1 on migration and invasion of MCF7 cells.
Zhang Y; Wu T; Zhao B; Liu Z; Qian R; Zhang J; Shi Y; Wan Y; Li Z; Hu X
Cancer Sci; 2022 Feb; 113(2):489-499. PubMed ID: 34839571
[TBL] [Abstract][Full Text] [Related]
18. Unveiling Arformoterol as a potent LSD1 inhibitor for breast cancer treatment: A comprehensive study integrating 3D-QSAR pharmacophore modeling, molecular docking, molecular dynamics simulations and in vitro assays.
Rezaei H; Zarezade V; Khodadadi I; Tavilani H; Tanzadehpanah H; Karimi J
Int J Biol Macromol; 2024 Feb; 258(Pt 2):129048. PubMed ID: 38159701
[TBL] [Abstract][Full Text] [Related]
19. Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
Milelli A; Marchetti C; Turrini E; Catanzaro E; Mazzone R; Tomaselli D; Fimognari C; Tumiatti V; Minarini A
Bioorg Med Chem Lett; 2018 Apr; 28(6):1001-1004. PubMed ID: 29496367
[TBL] [Abstract][Full Text] [Related]
20. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]